The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population.
about
Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidityCardiovascular risk in rheumatoid arthritis: assessment, management and next stepsMultimorbidity and Patient Safety Incidents in Primary Care: A Systematic Review and Meta-AnalysisCardiovascular comorbidity in rheumatic diseases: a focus on heart failureEvaluation of myocardial function in patients with rheumatoid arthritis using strain imaging by speckle-tracking echocardiography.Coronary Artery Disease Evaluation in Rheumatoid Arthritis (CADERA): study protocol for a randomized controlled trial.Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatmentIncreased prevalence of diastolic dysfunction in rheumatoid arthritis.Rheumatoid arthritis patients with active disease and no history of cardiac pathology have higher brain natriuretic peptide (BNP) levels than patients with inactive disease or healthy control subjects.Use of B-type natriuretic peptide as a screening tool for left ventricular diastolic dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease.Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis.Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions.A comparative study on serum lipoprotein (a) and lipid profile between rheumatoid arthritis patients and normal subjects.The influence of rheumatoid arthritis disease characteristics on heart failure.Preventing Heart Failure in Inflammatory and Immune DisordersMyocardial citrullination in rheumatoid arthritis: a correlative histopathologic study.The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases.Risk factors for asymptomatic ventricular dysfunction in rheumatoid arthritis patients.Development of reduced kidney function in rheumatoid arthritis.Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.Rheumatoid arthritis and cardiovascular diseaseDecreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?Cardiovascular comorbidity in rheumatic diseases.Comorbidities in Heart Failure: Are There Gender Differences?Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future Perspectives.Five-year changes in cardiac structure and function in patients with rheumatoid arthritis compared with the general population.Sudden cardiac death in patients with rheumatoid arthritisAdvanced myocardial tissue characterisation by a multi-component CMR protocol in patients with rheumatoid arthritis.Therapeutic Benefits of Tocilizumab Vary in Different Organs of a Patient with AA Amyloidosis.Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis.The Impact of Different Classification Criteria Sets on the Estimated Prevalence and Associated Risk Factors of Diastolic Dysfunction in Rheumatoid Arthritis.Retinal vessel morphology in rheumatoid arthritis: Association with systemic inflammation, subclinical atherosclerosis, and cardiovascular risk.Comorbidity in modern nursing: a closer look at heart failure.Prevalence of left ventricular dysfunction in rheumatoid arthritis.Subendocardial viability ratio in patients with rheumatoid arthritis: comparison with healthy controls and identification of prognostic factors.Absence of Fibrosis and Inflammation by Cardiac Magnetic Resonance Imaging in Rheumatoid Arthritis Patients with Low to Moderate Disease Activity.Characteristics of exercise capacity in female systemic lupus erythematosus associated pulmonary arterial hypertension patients.Bimodal Function of Anti-TNF Treatment: Shall We Be Concerned about Anti-TNF Treatment in Patients with Rheumatoid Arthritis and Heart Failure?Epidemiology of heart failure with preserved ejection fraction
P2860
Q24630655-773E14B5-28F0-424B-85EB-8EBB6E2F7050Q26744334-D63A9620-20C8-4E5F-BF0D-283BC71A9BC1Q26796372-C64CF87D-4ABC-4F8A-BBF8-E3F64C11587CQ26823443-714CBB7A-750A-4277-9617-8068892812C3Q30401698-4D7550EF-29E7-4D4C-B8CD-61E2F5D262BFQ30426026-F165ACF1-8794-4351-98CF-7CE93C0C0DDBQ33943374-2AA66D17-7613-4A77-A92D-5589C03EA7C5Q34061175-1D22209B-FCEC-45CD-BC0F-E2B56562FD64Q34357253-DAC81247-98DE-49E5-9331-D78D20833B24Q34970160-7E5C8EEC-C7BC-4CCB-AD0D-842FF02D70CFQ34986307-5F0CA802-F5CC-4EDD-A5F3-A557C312AA9DQ35019467-430C3459-1559-413B-8259-3C8736224EF8Q35121150-1C9C42B3-81DF-4A2D-A5B0-A6A7E0FF8C60Q35631101-F604C5B4-AEEB-4C46-A6AE-DC076D15C40AQ35915244-DC916054-BA43-43BD-893C-9BEDFCC4F1A1Q35994802-294DB357-4D04-404A-BDFD-5A3B70975AA6Q36085051-CB7D82DE-5D49-4DDC-B3B6-4E30813FA023Q37027093-4E2EAB8D-5400-4C29-A945-8F670AE3B21EQ37400763-36A9B87B-F946-43F9-9674-2972CB1DA5A4Q37620219-12C3FA7B-00C6-4420-92D2-5ED99BCB57F2Q37883018-7091F1C5-8CD1-4E90-9600-08EAA0FDA495Q38149252-F2E920B0-A7C2-448B-B54E-D702FFC2D89BQ38401848-D689F9DD-D117-454E-A6B6-D96E44662FC4Q38568465-205CDCCB-4052-4C5A-BE68-422812E347ECQ38717849-87013863-8059-4982-9CC2-5A0866B2A496Q38972344-B9864A84-782B-4092-9E4E-CC2AF437A002Q40233931-6993947C-65C3-47C3-941D-44A193A24BFAQ41264898-2FBEDC95-6074-406C-85D7-F15E840A3428Q42374261-BAFAFA0A-2328-4142-8A56-A2B4F917A43AQ42843261-1B3A73F0-07EB-4753-B97F-34C52310AABEQ46089585-A3DDFE95-79B7-4A5E-971C-52FC5DAD6EE3Q48214698-166EA235-6859-45A7-905B-EC3602065B67Q48323417-5973EB26-5DB3-43FE-AFD8-D086107B376AQ48696272-C2ED28A8-8A31-4189-A8A7-087C0CCA0C8AQ49387418-664CF58E-5D59-42E0-B719-C13FC93C6A40Q50690412-DE70285F-723F-4510-84B5-C07AD724D492Q52587395-DA591F9D-311D-469B-A65D-547DCAD28D1DQ55091651-89CCAFA4-6933-499E-BD74-66EEF0E54EFCQ55691195-77DA9667-2A8F-4D6F-8958-C7D2AF659E97Q57308303-D27B3566-6469-4E55-AD95-7DA6EAF5E9C5
P2860
The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The presentation and outcome o ...... hat in the general population.
@en
The presentation and outcome o ...... hat in the general population.
@nl
type
label
The presentation and outcome o ...... hat in the general population.
@en
The presentation and outcome o ...... hat in the general population.
@nl
prefLabel
The presentation and outcome o ...... hat in the general population.
@en
The presentation and outcome o ...... hat in the general population.
@nl
P2093
P2860
P356
P1476
The presentation and outcome o ...... that in the general population
@en
P2093
Cynthia S Crowson
Hilal Maradit Kremers
Sherine E Gabriel
Terry M Therneau
Véronique L Roger
P2860
P304
P356
10.1002/ART.23798
P50
P577
2008-09-01T00:00:00Z